Entinostat and high-dose Interleukin 2 in renal cell carcinoma patients

Gemcitabine plus cisplatin plus ipilimumab for metastatic urothelial cancer

Avelumab for metastatic urothelial carcinoma: JAVELIN trial

Subgroup analyses of METEOR; randomized phase III trial of cabozantinib vs everolimus for RCC

Integrated genomic correlates of response to PD-1 inhibitor nivolumab in mRCC

Discontinuing VEGF-targeted therapy for progression or toxicity affects outcomes of second-line therapies in mRCC

Impact of metformin on outcomes for metastatic renal cell carcinoma

Comparing adjuvant radiotherapy plus chemo vs. adjuvant chemo following cystectomy for bladder cancer

Molecular genetics of testicular cancer: What does the clinician need to know?

ASCO GU 2016: Highlights

Atezolizumab for platinum-treated locally advanced or metastatic urothelial carcinoma

Healthcare and QoL burden of symptomatic skeletal events in CRPC with bone mets